Drug Pricing Transparency and Accountability Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Sep 30, 2021)
Drug Pricing Transparency and Accountability Act
This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.
What just happenedOct 1, 2021
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseSep 30, 2021
- Oct 1, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Sep 30, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Sep 30, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Sep 30, 2021IntroReferralIntro-H
Introduced in House
- Sep 30, 2021IntroReferral1000
Introduced in House